The prognostic value of p53 nuclear overexpression and MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder

Cancer

Volumn 80, Issue 8, 1997, Pages 1472-1481

  Popov, Zivko ^a   Hoznek, Andras ^b   Colombel, Marc ^b   Bastuji Garin, Sylvie ^b   Lefrere Belda, Marie Aude ^b   Bellot, Jacqueline ^b   Abbou, Claude C ^b   Mazerolles, Catherine ^c   Chopin, Dominique K ^b  

^a SS CYRIL AND METHODIUS UNIVERSITY   (Macedonia)

^b HENRI MONDOR HOSPITAL   (France)

^c CHU PURPAN   (France)

Author keywords

Bladder carcinoma; Molecular markers; P53; Prognostic factor; Proliferation

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CELL PROLIFERATION; DIAGNOSTIC VALUE; FEMALE; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSITIONAL CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

ANTIBODIES, MONOCLONAL; CARCINOMA, TRANSITIONAL CELL; CELL DIVISION; CELL NUCLEUS; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 0030826329     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19971015)80:8<1472::AID-CNCR15>3.0.CO;2-2     Document Type: Article

References (49)

1. Jewett HJ, Strong GH. Infiltrating carcinoma of the bladder: relation of depth of penetration of the bladder wall to incidence of local extension and metastasis. J Urol 1946;55:366-72.
2. Kaye KW, Lange PH. Mode of presentation of invasive bladder cancer: reassessment of the problem. J Urol 1982;128:31.
3. TNM Atlas. Illustrated guide to the TNM/pTNM classification of malignant cancer. 2nd revised edition. International Union Against Cancer. Berlin: Springer Verlag, 1992:274-9.
4. Herr HW, Jakse G, Sheinfeld J. T1 bladder tumor. Semin Urol 1990;8:254-61.
5. Herr HW, Laudone W, Badalament RA, Oettgen HF, Sogani PC, Freedman BD, et al. Bacillus Calmette-Guérin therapy alters the progression of superficial bladder cancer. J Clin Oncol 1988;6:1450-5.
6. Malkowicz SB, Nichols P, Lieskovsky G, Boyd ST, Huffman J, Skinner DG. The role of radical cystectomy in the management of high-grade superficial bladder cancer (PA, P1, PIS and P2). J Urol 1990;144:641-5.
7. Pagano F, Bassi P, Galetti TP, Meneghini A, Milani C, Artibani W, et al. Results of contemporary radical cystectomy for invasive bladder cancer: a clinicopathological study with emphasis on the inadequacy of the tumor nodes and metastases classification. J Urol 1991;145:45-50.
8. Nowell PC. Mechanisms of tumor progression. Cancer Res 1986;46:2203-7.
9. Chopin DK, Popov Z, Ravery V, Bellot J, Hoznek A, Patard JJ, et al. Prognostic factors in superficial bladder cancer. World J Urol 1993;11:148-52.
10. Herr HW. Conservative management of muscle-infiltrating bladder cancer: prospective experience. J Urol 1987;138:1162.
11. Levine AJ, Momand J, Finlay CA. The p53 suppressor gene. Nature 1991;351:453-6.
12. Finlay CA, Hinds PW, Levine AJ. The p53 proto-oncogene can act as a suppressor of transformation. Cell 1989;57:1083.
13. Levine AJ, Perry MF, Chang A, Silver A, Dittmer D, Wu M, et al. The role of the p53 tumour suppressor gene in tumorigenesis. The 1993 Walter Hubert Lecture. Br J Cancer 1994;69:3.
14. Finlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M, Levine A. Activating mutations for transformation by p53 produce a gene product that forms an k5c70-p53 complex with an altered half-life. Mol Cell Biol 1988;8:531-9.
15. Sidransky D, Von Eschenbach A, Tsai YC, Jones P, Summerhayes I, Marshall F, et al. Identification of p53 gene mutations in bladder cancers and urine samples. Science 1991;252:706-9.
16. Fujimoto K, Yamada Y, Okajima E, Kakizoe T, Sasaki H, Sugimura T, et al. Frequent association of p53 gene mutation in invasive bladder cancer. Cancer Res 1992;52:1393-8.
17. Esrig D, Spruck CH III, Nichols PW, Chaiwun B, Steven K, Groshen S, et al. p53 nuclear protein accumulation correlates with mutations in the p53 gene tumor grade and stage in bladder cancer. Am J Pathol 1993;143:1389-97.
18. Cordon-Cardo C, Dalbagni G, Saez GT, Oliva MR, Zhang ZF, Rosai J, et al. p53 mutations in human bladder cancer: genotypic versus phenotypic patterns. Int J Cancer 1994; 56:347-53.
19. Lipponen PK. Over-expression of p53 nuclear oncoprotein in transitional cell bladder cancer and its prognostic value. Int J Cancer 1993;53:365-70.
20. Sarkis AS, Dalbagni G, Cordon-Cardo C, Zhang ZF, Sheinfeld J, Fair WR, et al. Nuclear over-expression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst 1993;85:53-9.
21. Lipponen PK, Eskelinen MJ. Cell proliferation of transitional cell bladder tumours determined by PCNA/cyclin immunostaining and its prognostic value. Br J Cancer 1992;66: 171-6.
22. Gerdes J. Ki-67 and other proliferation markers useful for immunohistological diagnostic and prognostic evaluations in human malignancies. Semin Cancer Biol 1990;1:199-206.
23. Cattoretti G, Becker MH, Key G, Duchrow M, Schluter C, Galle J, et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB-1 and MIB-3) detect proliferating cells in microwave-processed formaline fixed paraffin sections. J Pathol 1992;168:357-63.
24. Mazerolles C, Rishmann P, Chopin D, Popov Z, Malavaud B, Selves J, et al. Usefulness of MiB1 monoclonal antibody in assessing the proliferative index in human bladder carcinoma: comparison with Ki-67 antibody. Histopathology 1994;25:563-8.
25. Mulder AH, Van Hootegem JC, Sylvester R, ten Kate FJ, Kurth KH, Ooms EC, et al. Prognostic factors in bladder carcinoma: histologic parameters and expression of a cell cycle related nuclear antigen (Ki-67). J Pathol 1992;166:37-43.
26. Mostofi FK, Sobin LH, Torloni H. International histological classification of tumours no. 10: histological typing in urinary bladder tumours. Geneva: World Health Organization, 1973.
27. Herr HW, Badalament RA, Amato DA, Laudone VP, Fair WR, Whitmore WF. Superficial bladder cancer treated with bacillus Calmette-Guérin: a multivariate analysis of factors affecting tumor progression. J Urol 1989;141:22-9.
28. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ARC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981;29:577-80.
29. Cordell JL, Falini B, Erber WN, Ghosh AK, Abdulaziz Z, MacDonald S, et al. Immunoenzymatic labelling of monoclonal antibodies using immune complexes of alkaline phosphatase and anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem 1984;32:219.
30. Gerdes J, Li L, Schlueter C, Duchrow M, Wohlenberg C, Gerlach C, Stahmer I, et al. Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki67. Am J Pathol 1991;138:867-73.
31. Simon RM. Design and conduct of clinical trials. In: DeVita VT Jr., Hellman S, Rosenberg SA. Cancer principles and practice of oncology. Volume 1. 3rd edition. Philadelphia: Lippincott, 1989:396-420.
32. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977;35:1-39.
33. Esrig D, Elmajian D, Groshen S, Freeman JA, Stein JP, Chen SC, et al. Accumulation of p53 and tumor progression in bladder cancer. New Engl J Med 1994;331:1259-64.
34. Sarkis AS, Dalbagni G, Cordon-Cardo C, Melamed J, Zhang ZF, Sheinfeld J, et al. Association of p53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. J Urol 1994;152:388-92.
35. Sarkis AS, Bajorin DF, Reuter VE, Herr HW, Netto G, Zuo-Feng Zhang G, et al. Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. J Clin Oncol 1995;13:384-90.
36. Gardiner RA, Walsh MD, Allen V, Rahman S, Samaratunga MLTH, Seymour GJ, et al. Immunohistological expression of p53 in primary pT1 transitional cell bladder cancer in relation to tumour progression. Br J Urol 1994;73:526-32.
37. Thomas DJ, Robinson MC, Charlton R, Wilkinson S, Shenton BK, Neal DE. p53 expression, ploidy and progression in pT1 transitional cell carcinoma of the bladder. Br J Urol 1993; 73:533-7.
38. Mercer WE, Nelson D, Deleo AB, Olo J, Baserga R. Microinjection of monoclonal antibody to protein p53 inhibits serum-induced DNA synthesis in 3T3 cells. Proc Natl Acad Sci U S A 1982;79:6309-12.
39. Mazars R, Pujol P, Maudelonde T, Jeanteur P, Theillet C. p53 mutations in ovarian cancer: a late event? Oncogene 1991;6:1685-90.
40. Sidransky D, Mikkelsen T, Schwech-Heimer K, Rosenblum ML, Cavanee W, Vogelstein B. Clonal expansion of p53 mutant cells is associated with brain tumor progression. Nature 1992;355:846-7.
41. Soini Y, Turpeenniemi-Hujanen T, Kamel D, Autio-Harmainen H, Ristelli I, Ristclli L, et al. p53 immunohistochemistry in transitional cell carcinoma and dysplasia of the urinary bladder correlates with disease progression. Br J Cancer 1993;68:1029-35.
42. Maestro R, Dolcetti R, Gasparotto D, Doglioni C, Pelucchi S, Barzan L, et al. High frequency of p53 gene alterations associated with protein overexpression in human squamous cell carcinoma of the larynx. Oncogene 1992;7:1159-66.
43. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53 associated protein in human sarcomas. Nature 1992;358:80-2.
44. Lipponen PK, Eskelinen MJ, Nordline S. Progression and survival in transitional cell bladder cancer: a comparison of established prognostic factors, S phase fraction and DNA ploidy. Eur J Cancer 1991;27:877-81.
45. Szyblaski W. X-ray sensitization by halopyromidines. Cancer Chemother Rep 1974;58:539.
46. Tribukait B. Flow cytometry in assessing the clinical aggressiveness of genitourinary neoplasms. World J Urol 1984;5:108-22.
47. Shiina H, Igawa M, Nagami H, Yagi H, Urakami S, Yoneda T, et al. Immunohistochemical analysis of proliferating cell nuclear antigen, p53 protein and nm23 protein, and nuclear DNA content in transitional cell carcinoma of the bladder. Cancer 1996;78:1762-74.
48. Sidransky D, Frost P, Von Eschenbach A, Oyasu R, Presinger AC, Vogelstein B. Clonal origin of bladder cancer. N Engl J Med 1992;326:737-40.
49. Spruck CH III, Ohneseit PF, Gonzaley.-Xulueta M, Hsrig D, Miyao N, Tsai YC, et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 1992;54: 784-8.